Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan rollover study in metastatic solid tumors
NCT04319198Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2020
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 4, open-label trial of sacituzumab govitecan in metastatic solid tumors (3 arms), sponsored by Gilead Sciences. Primary endpoints: Adverse Events up to 3.9 years, Serious Adverse Events up to 3.9 years and 1 more. Started Aug 2020; status: completed.
02
Drugs
sacituzumab govitecan
03
Conditions
metastatic solid tumors
Beyond the preview
Go deeper on NCT04319198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04319198.